Market Cap 5.45B
Revenue (ttm) 3.70B
Net Income (ttm) 280.09M
EPS (ttm) N/A
PE Ratio 21.24
Forward PE 20.59
Profit Margin 7.57%
Debt to Equity Ratio 0.25
Volume 101,548
Avg Vol 397,996
Day's Range N/A - N/A
Shares Out 32.36M
Stochastic %K 38%
Beta 0.18
Analysts Sell
Price Target $175.50

Company Profile

FTI Consulting, Inc. provides business advisory services to manage change, mitigate risk, and resolve disputes worldwide. The company operates through Corporate Finance & Restructuring; Forensic and Litigation Consulting; Economic Consulting; and Technology, and Strategic Communications segments. The Corporate Finance & Restructuring segment provides business transformation and strategy, transactions, and turnaround and restructuring services. The Forensic and Litigation Consulting segment offer...

Industry: Consulting Services
Sector: Industrials
Phone: 202 312 9100
Fax: 202 312 9101
Address:
555 12th Street NW, Suite 700, Washington, United States
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 29 at 10:33 PM
$LMDX $FCN $RHHBY $NDAQ Happy 1 year anniversary $RHHBY from robbing $LMDX Shareholders! Our Time will Come! The most recent formal statement from Roche concerning LumiraDx appears in its July 29, 2024 media release announcing the completion of the acquisition of LumiraDx’s point‑of‑care technology. In that statement, Matt Sause, CEO of Roche Diagnostics, said: “Access to diagnostic testing is critical for the delivery of healthcare worldwide and we are confident that the LumiraDx platform and technology will help us expand the availability of testing, especially in settings such as primary care and low and middle income countries.”  From LumiraDx—with the CEO, Veronique Ameye, stating: “We are absolutely delighted to continue our journey as part of Roche Diagnostics … Being an integral part of the Roche network opens the door to realising the full potential of our Point of Care technology, and to increasing patient access to community‑based healthcare around the world.”
0 · Reply
NVDAMillionaire
NVDAMillionaire Jul. 29 at 4:42 PM
$FCN Outstanding article that hits the mark on FCN's current state. So if you want to refresh your FCN insights or learn about FCN from scratch, this is a must read. https://beyondspx.com/article/fti-consulting-resilience-forged-in-headwinds-powering-long-term-growth-nyse-fcn
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 29 at 4:04 AM
$FCN $LMDX $NDAQ $RHHBY 🚨 LMDX Shareholders We Got Screwed 🚨 LumiraDx was not a normal bankruptcy. • $295M went to pay off insiders & secured lenders • Shareholders got ZERO • Then Zwanziger, Scott & McAleer quietly launched ElectraDx — same business, new name, no debt • Veronique Ameye dismantled the company… then took a role with Roche • The Gates-funded TB test? Gone. Patents continued after liquidation. Value never disclosed. This was a coordinated asset grab and shareholders were out of sight and mind throughout the whole process. Don’t let them erase us. Don’t let them walk with the tech that we helped invest in while we’re left holding the bag. #LMDX #LumiraDx #Roche #ElectraDx #ShareholderJustice #Fraud
1 · Reply
ZacksResearch
ZacksResearch Jul. 25 at 3:48 PM
$FCN posts strong Q2 beats, but the stock stays flat. What's the catch? 🤔 🔍 EPS beat by 14%, yet down 9% YoY 📉 Revenue slightly down YoY despite consensus beat 📊 Economic Consulting & Tech revenues drop, while Strategic Comms grows 20.8% mainly due to an $8.4M rise in pass-through revenues; Forensic & Litigation Consulting up 10% Full breakdown here 👉 https://www.zacks.com/stock/news/2617628/fti-consulting-stock-remains-flat-since-q2-earnings-beat?cid=sm-stocktwits-2-2617628-body-3968&ADID=SYND_STOCKTWITS_TWEET_2_2617628_BODY_3968
0 · Reply
ZacksResearch
ZacksResearch Jul. 25 at 2:28 PM
$FCN beats on Q2 earnings — so why is the stock going nowhere? Even with the earnings surprise, shares have stayed flat, signaling muted investor reaction. Full story on what’s holding FCN back 👉 https://www.zacks.com/stock/news/2617628/fti-consulting-stock-remains-flat-since-q2-earnings-beat?cid=sm-stocktwits-2-2617628-teaser-3904&ADID=SYND_STOCKTWITS_TWEET_2_2617628_TEASER_3904
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 25 at 8:34 AM
$FCN $LMDX $NDAQ $RHHBY This is not just mismanagement — it is fraud. It is a betrayal of trust, a corporate sleight of hand that left thousands of investors with nothing while insiders walked away with everything. #gates #truth #fraud #sec
1 · Reply
jtrader8000
jtrader8000 Jul. 25 at 5:38 AM
$FCN FCN - not Fixed Coupon Notes - stock tends to trend nicely once its on its way, hopefully this earnings bounce is a good kick off point for the next leg higher, so good risk/reward on offer
0 · Reply
CatCapital_ai
CatCapital_ai Jul. 24 at 11:32 AM
$FCN Earnings - Q2/2025 Revenue: $943.7M ✅ vs. $912.71M est. EPS: $2.13 ✅ vs. $1.9 est. FTI Consulting raises full-year 2025 revenue guidance to $3.66-$3.76B amid resilient segments; expects EPS of $7.24-$7.84.
0 · Reply
DmcMouse
DmcMouse Jul. 24 at 8:38 AM
$LMDX $LMDX $RHHBY $FCN $NDAQ Roche just reported CHF 2.2 billion (~$2.47B USD) in “Near-Patient Care” revenue. That’s the LumiraDx platform — CRP, D-Dimer, HbA1c, NT-proBNP — exactly what shareholders funded. We backed the company. We held the shares. Then they: Liquidated offshore Shifted the tech to Roche Filed a 125M ADR F-6EF (0.77 RHHBY per LMDXF) Never delivered our conversion This isn’t just restructuring. It’s erasure. If the platform is good enough to generate billions, it’s good enough to honor our equity. We’re still here. And we’re still watching. #LMDXF #ShareholderJustice #RocheKnows #WhereAreMyShares
4 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 24 at 2:29 AM
$FCN $LMDX $NDAQ $RHHBY Ron got ElectraDx. Veronique got Roche. FTI got paid. Bill Gates got to follow the TB tech. And shareholders? They got deleted.
0 · Reply
Latest News on FCN
FTI Consulting, Inc. (FCN) Q2 2025 Earnings Call Transcript

Jul 24, 2025, 2:22 PM EDT - 14 days ago

FTI Consulting, Inc. (FCN) Q2 2025 Earnings Call Transcript


FTI Consulting Reports Second Quarter 2025 Financial Results

Jul 24, 2025, 7:30 AM EDT - 14 days ago

FTI Consulting Reports Second Quarter 2025 Financial Results


FTI Consulting Announces Technology Alliance with BigID

May 20, 2025, 7:30 AM EDT - 2 months ago

FTI Consulting Announces Technology Alliance with BigID


FTI Consulting, Inc. (FCN) Q1 2025 Earnings Call Transcript

Apr 24, 2025, 5:35 PM EDT - 3 months ago

FTI Consulting, Inc. (FCN) Q1 2025 Earnings Call Transcript


FTI Consulting Reports First Quarter 2025 Financial Results

Apr 24, 2025, 7:30 AM EDT - 3 months ago

FTI Consulting Reports First Quarter 2025 Financial Results


lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 29 at 10:33 PM
$LMDX $FCN $RHHBY $NDAQ Happy 1 year anniversary $RHHBY from robbing $LMDX Shareholders! Our Time will Come! The most recent formal statement from Roche concerning LumiraDx appears in its July 29, 2024 media release announcing the completion of the acquisition of LumiraDx’s point‑of‑care technology. In that statement, Matt Sause, CEO of Roche Diagnostics, said: “Access to diagnostic testing is critical for the delivery of healthcare worldwide and we are confident that the LumiraDx platform and technology will help us expand the availability of testing, especially in settings such as primary care and low and middle income countries.”  From LumiraDx—with the CEO, Veronique Ameye, stating: “We are absolutely delighted to continue our journey as part of Roche Diagnostics … Being an integral part of the Roche network opens the door to realising the full potential of our Point of Care technology, and to increasing patient access to community‑based healthcare around the world.”
0 · Reply
NVDAMillionaire
NVDAMillionaire Jul. 29 at 4:42 PM
$FCN Outstanding article that hits the mark on FCN's current state. So if you want to refresh your FCN insights or learn about FCN from scratch, this is a must read. https://beyondspx.com/article/fti-consulting-resilience-forged-in-headwinds-powering-long-term-growth-nyse-fcn
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 29 at 4:04 AM
$FCN $LMDX $NDAQ $RHHBY 🚨 LMDX Shareholders We Got Screwed 🚨 LumiraDx was not a normal bankruptcy. • $295M went to pay off insiders & secured lenders • Shareholders got ZERO • Then Zwanziger, Scott & McAleer quietly launched ElectraDx — same business, new name, no debt • Veronique Ameye dismantled the company… then took a role with Roche • The Gates-funded TB test? Gone. Patents continued after liquidation. Value never disclosed. This was a coordinated asset grab and shareholders were out of sight and mind throughout the whole process. Don’t let them erase us. Don’t let them walk with the tech that we helped invest in while we’re left holding the bag. #LMDX #LumiraDx #Roche #ElectraDx #ShareholderJustice #Fraud
1 · Reply
ZacksResearch
ZacksResearch Jul. 25 at 3:48 PM
$FCN posts strong Q2 beats, but the stock stays flat. What's the catch? 🤔 🔍 EPS beat by 14%, yet down 9% YoY 📉 Revenue slightly down YoY despite consensus beat 📊 Economic Consulting & Tech revenues drop, while Strategic Comms grows 20.8% mainly due to an $8.4M rise in pass-through revenues; Forensic & Litigation Consulting up 10% Full breakdown here 👉 https://www.zacks.com/stock/news/2617628/fti-consulting-stock-remains-flat-since-q2-earnings-beat?cid=sm-stocktwits-2-2617628-body-3968&ADID=SYND_STOCKTWITS_TWEET_2_2617628_BODY_3968
0 · Reply
ZacksResearch
ZacksResearch Jul. 25 at 2:28 PM
$FCN beats on Q2 earnings — so why is the stock going nowhere? Even with the earnings surprise, shares have stayed flat, signaling muted investor reaction. Full story on what’s holding FCN back 👉 https://www.zacks.com/stock/news/2617628/fti-consulting-stock-remains-flat-since-q2-earnings-beat?cid=sm-stocktwits-2-2617628-teaser-3904&ADID=SYND_STOCKTWITS_TWEET_2_2617628_TEASER_3904
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 25 at 8:34 AM
$FCN $LMDX $NDAQ $RHHBY This is not just mismanagement — it is fraud. It is a betrayal of trust, a corporate sleight of hand that left thousands of investors with nothing while insiders walked away with everything. #gates #truth #fraud #sec
1 · Reply
jtrader8000
jtrader8000 Jul. 25 at 5:38 AM
$FCN FCN - not Fixed Coupon Notes - stock tends to trend nicely once its on its way, hopefully this earnings bounce is a good kick off point for the next leg higher, so good risk/reward on offer
0 · Reply
CatCapital_ai
CatCapital_ai Jul. 24 at 11:32 AM
$FCN Earnings - Q2/2025 Revenue: $943.7M ✅ vs. $912.71M est. EPS: $2.13 ✅ vs. $1.9 est. FTI Consulting raises full-year 2025 revenue guidance to $3.66-$3.76B amid resilient segments; expects EPS of $7.24-$7.84.
0 · Reply
DmcMouse
DmcMouse Jul. 24 at 8:38 AM
$LMDX $LMDX $RHHBY $FCN $NDAQ Roche just reported CHF 2.2 billion (~$2.47B USD) in “Near-Patient Care” revenue. That’s the LumiraDx platform — CRP, D-Dimer, HbA1c, NT-proBNP — exactly what shareholders funded. We backed the company. We held the shares. Then they: Liquidated offshore Shifted the tech to Roche Filed a 125M ADR F-6EF (0.77 RHHBY per LMDXF) Never delivered our conversion This isn’t just restructuring. It’s erasure. If the platform is good enough to generate billions, it’s good enough to honor our equity. We’re still here. And we’re still watching. #LMDXF #ShareholderJustice #RocheKnows #WhereAreMyShares
4 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 24 at 2:29 AM
$FCN $LMDX $NDAQ $RHHBY Ron got ElectraDx. Veronique got Roche. FTI got paid. Bill Gates got to follow the TB tech. And shareholders? They got deleted.
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 24 at 2:28 AM
$FCN $LMDX $NDAQ $RHHBY The Setup “This is not a sale of the company.” — LumiraDx, December 2023 press release Truth: By July 2024, Roche had acquired the core diagnostic platform. Veronique Ameye had become CEO and General Counsel—then transitioned to work with Roche. Ron Zwanziger stepped down due to a “conflict of interest”… …and resurfaced at ElectraDx, armed with ex-LumiraDx staff and tech. Shareholders were never offered a vote. No fairness opinion. No SEC-required disclosures. No return.
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 24 at 2:24 AM
$FCN $LMDX $NDAQ $RHHBY The only transparency we got was the kind you see after a company is gutted, sold, and stripped bare. Roche got the diagnostics. Veronique got the titles. Ron got the team. We got the shaft.
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 24 at 2:23 AM
$FCN $LMDX $NDAQ $RHHBY LumiraDx had: – FDA-cleared tech – A global footprint – Billion-dollar IP So why’d it sell for crumbs? Because Ron, Veronique, and Roche weren’t in it for shareholders— They were in it for each other.
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 24 at 2:22 AM
$FCN $LMDX $NDAQ $RHHBY They called it a “select asset sale.” Ron got ElectraDx. Veronique got Roche. FTI got fees. Shareholders? They got gaslit.
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 24 at 2:20 AM
$LMDX $RHHBY $FCN $NDAQ LumiraDx was a $5 billion promise… Then Ron vanished to ElectraDx, Veronique dissolved the evidence, and Roche scooped the tech for pennies. FTI called it a “wind-down.” We call it a heist in daylight.
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 23 at 12:31 PM
$FCN $LMDX $RHHBY Step 4: Call the Cleaners FTI Consulting steps in to “wind down.” The JOLs send one last email: 🪦 “Liquidation complete. Please stop asking questions.” And just like that, it’s all gone. The Result? ✅ Roche owns the future. ✅ Veronique and Ron keep control. ✅ Gates and Roche still praises the TB tech. ❌ Shareholders get wiped out without a seat at the table. This wasn’t a restructuring. It was a surgical asset extraction—wrapped in legal paperwork, hidden offshore, and sold to the lowest bidder. @SECGov. Demand answers. They didn’t just fail us. They erased us. #LMDX #ShareholderJustice #InvestigateLumiraDx #RocheKnows #ElectraDxExpose
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 23 at 12:29 PM
$LMDX $RHHBY $FCN $SPY $NDAQ #billgates #sec Here’s a Good Joke since the Jokes on us…. Let’s keep going… How to Rob a $5B Company Without a Mask Starring: Veronique, Ron, Roche, FTI Consulting, and the JOLs. #LumiraDx #CorporateHeist #ShareholderFraud Step 1: Put Your People in Charge Veronique becomes CEO, General Counsel, and director of nearly every subsidiary. Ron Zwanziger? He builds the empire… then exits stage left claiming a “conflict of interest.” (Spoiler: He comes back in Act II with ElectraDx and your stolen tech.) Step 2: Sell the Crown Jewels—Quietly Roche buys the point-of-care platform, TB IP, and diagnostics pipeline for $295M. No vote. No transparency. Just a press release calling it “select assets.” Shareholders? Not even cc’d. Step 3: Reward the Insiders Veronique lands soft—possibly at Roche. Ron resurfaces with the same team and tech at ElectraDx. Roche gets a billion-dollar platform for pennies and zero accountability. You? You get delisted and deleted.
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 23 at 12:19 PM
$LMDX $FCN $RHHBY #SEC #TRUTH Here’s a good joke…. Why did FTI Consulting take the job liquidating LumiraDx? Because it’s easy money when the insiders hand you the script, and the shareholders aren’t invited to the funeral. They didn’t wind down a company— they buried the body, burned the records, and billed by the hour. #Keep searching for the Truth! #pay lmdx shareholders what is owed!
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 23 at 4:41 AM
$FCN $LMDX $NDAQ $RHHBY ⸻ 🗓️ March 2024 – Subsequent Press Mentions “The addition of the LumiraDx technology to our diagnostic portfolio will enable us to transform testing at the point of care.” — Matt Sause, CEO of Roche Diagnostics (echoed across multiple press articles)
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 23 at 4:40 AM
$LMDX $RHHBY $NDAQ $FCN #Fraud December 29, 2023 – Definitive Agreement Announcement “The addition of the LumiraDx technology to our diagnostics portfolio will enable us to transform testing at the point of care.” “LumiraDx has developed a highly versatile platform that delivers strong performance across multiple disease areas and technologies. We believe this will enable better patient access to timely results in decentralized healthcare settings worldwide.” — Matt Sause, CEO of Roche Diagnostics  ⸻ 🗓️ July 29, 2024 – Acquisition Close Announcement “Access to diagnostic testing is critical for the delivery of healthcare worldwide and we are confident that the LumiraDx platform and technology will help us expand the availability of testing, especially in settings such as primary care and low and middle income countries.” — Matt Sause, CEO of Roche Diagnostics
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 23 at 4:38 AM
$FCN $LMDX $RHHBY $SPY Ron Zwanziger 🗓️ December 14, 2022 – Gates Foundation Grant for TB Test “The advancement of our TB molecular test signifies an important step forward in LumiraDx’s mission to increase access to accurate and affordable testing worldwide as well as an important step forward in our molecular testing technology.” “The support from the Gates Foundation is critical in our development of the TB test and ensuring it reaches communities where access to testing is most challenged. The availability of these immediate results can be game-changing.” (Source: PharmaFocus, Biospace)
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 23 at 4:38 AM
$FCN $LMDX $RHHBY $SPY 🗓️ August 18, 2022 – Q2 2022 Earnings Release “We have made significant progress on expanding our portfolio of newly authorized products and have exciting commercialization priorities.” “We are moving to commercialize our product portfolio in Europe and other international markets while actively working on U.S. submissions and preparing clinical trials this fall.” “We are confident these actions and strategic priorities for the next 12 to 18 months will bridge us toward key revenue milestones and support our strategy to transform community-based care.” (Source: GlobeNewswire)
0 · Reply